Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 2, 2011, Pages 112-116

  Krag, Aleksander ^a   Pedersen, Erling B ^b   Møller, Søren ^a   Bendtsen, Flemming ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

Author keywords

ascites; cirrhosis; ENaC; plasma cAMP; sodium excretion; Terlipressin

Indexed keywords

ALDOSTERONE; AQUAPORIN 2; CREATININE; CYCLIC AMP; EPITHELIAL SODIUM CHANNEL; NORADRENALIN; RENIN; SODIUM; TERLIPRESSIN; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; WATER;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; BOLUS INJECTION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SODIUM ABSORPTION; SODIUM URINE LEVEL; URINARY EXCRETION; WATER RETENTION;

ANTIHYPERTENSIVE AGENTS; CYCLIC AMP; DEMOGRAPHY; EPITHELIAL SODIUM CHANNEL; FEMALE; HUMANS; KIDNEY; LIVER CIRRHOSIS; LYPRESSIN; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; SODIUM; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 79952411391     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.537369     Document Type: Article

References (27)

1. Ioannou G, Doust J, Rockey DC Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;CD002147.
2. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51: 576-84.
3. Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25:1105-40.
4. Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-71.
5. Krag A, Bendtsen F, Pedersen EB, Holstein-Rathlou NH, Møller S. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am J Physiol Renal Physiol 2008;295:F1295-300.
6. Hyun JJ, Seo YS, Lee KG, Keum B, Yim HJ, Jeen YT, Chun HJ, Um SH, Kim CD, Ryu HS. Terlipressin-induced hyponatremic seizure. Scand J Gastroenterol 2010;45: 501-4.
7. Bruha R, Marecek Z, Prochazka V, Lata J, Spicak J, Ehrmann J, Kroupa R, Petrtyl J, Dolina J, Taimr P, Drastich P, Urbanek P, Vrzalova D. Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlip-ressin treatment of bleeding esophageal varices. Hepatogas-troenterology 2009;56:390-4.
8. Krag A, Hobolth L, Møller S, Bendtsen F. Hyponatraemia during terlipressin therapy. Gut 2010;59:417-8.
9. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994;203:72-9. (Pubitemid 24281062)
10. Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1-and V2-vasopressinergic recep-tors. Am J Physiol 1988;255:H261-5.
11. Boyle WA, III, Segel LD. Direct cardiac effects of vasopres-sin and their reversal by a vascular antagonist. Am J Physiol 1986;251:H734-41.
12. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007;35:33-40. (Pubitemid 46035674)
13. Treschan TA, Peters J. The vasopressin system: phy-siology and clinical strategies. Anesthesiology 2006;105: 599-612. (Pubitemid 44310444)
14. Fenton RA, Knepper MA. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev 2007;87:1083-112. (Pubitemid 350033821)
15. Nielsen S, Frøkiær J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205-44. (Pubitemid 34654219)
16. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90. (Pubitemid 32718586)
17. Schafer JA. Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct. Am J Physiol Renal Physiol 2002;283:F221-35. (Pubitemid 34778984)
18. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG. Vasopressin-V2 receptor stimulation reduces sodium excre-tion in healthy humans. J Am Soc Nephrol 2005;16:1920-8. (Pubitemid 41716422)
19. Ahloulay M, Dechaux M, Hassler C, Bouby N, Bankir L. Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J Clin Invest 1996;98:2251-8. (Pubitemid 26394198)
20. Bankir L, Martin H, Dechaux M, Ahloulay M. Plasma cAMP: a hepatorenal link influencing proximal reabsorption and renal hemodynamics? Kidney Int Suppl 1997;59:S50-6.:S50-6. (Pubitemid 27252821)
21. Ahloulay M, Bankir L, Lugnier C, Le BA, Poirel O, Moreau R, Lebrec D. Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites. Liver Int 2005;25:403-9.
22. Bankir L, Ahloulay M, Devreotes PN, Parent CA. Extracel-lular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved? Am J Physiol Renal Physiol 2002;282:F376-92. (Pubitemid 34654526)
23. Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol 2001;280:F860-7.
24. Lauridsen TG, Vase H, Bech JN, Nielsen S, Pedersen EB. Direct effect of methylprednisolone on renal sodium and water transport via the principal cells in the kidney. Eur J Endocrinol 2010;162:961-9.
25. Lauridsen TG, Vase H, Starklint J, Bech JN, Pedersen EB. Protein-enriched diet increases water absorption via the aquaporin-2 water channels in healthy humans. Nephrol Dial Transplant 2010;25:2502-10.
26. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 2008;19:1721-31.
27. Liard JF. cAMP and extrarenal vasopressin V2 receptors in dogs. Am J Physiol 1992;263:H1888-91.